CervoMed Inc. last reported quarterly results on Aug 10, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $0 (-100.0% year over year). It usually reports 41–48 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 9, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 10, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 41–48 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-100.0%
|
-7
-5.0%
|
—
|
|
May 18, 2026
48 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-100.0%
|
-8
-62.7%
|
—
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-83.4%
|
-8
-62.5%
|
—
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2
-46.6%
|
-6
-170.1%
|
—
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
-18.3%
|
-5
-94.6%
|
—
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
2
+27.1%
|
-5
-321.1%
|
-0.55
+21.4%
|
|
Aug 15, 2024
46 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
Apr 5, 2024
5 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRVO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1053691
- Former names
- Diffusion Pharmaceuticals Inc. (until Aug 14, 2023); RestorGenex Corp (until Jan 14, 2016); Stratus Media Group, Inc (until Mar 7, 2014); FERIS INTERNATIONAL, INC. (until Jul 16, 2008); TITAN MOTORCYCLE CO OF AMERICA INC (until Feb 22, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.